Login / Signup

Sodium-glucose co-transporter 2 inhibitors and hematopoiesis.

Habib YaribeygiMina MalekiFatemeh NasimiAlexandra E ButlerTannaz JamialahmadiAmir Hossein Sahebkar
Published in: Journal of cellular physiology (2022)
Many patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a relatively new class of antidiabetic drugs with confirmed protective effects in kidney and cardiovascular tissues. Recent evidence suggests that these drugs may provide additional benefits in enhancing hematopoietic processes in diabetic patients. Though the exact mediating pathways have not been fully elucidated, cellular mechanisms are likely involved. In the current study, we present the potential pathways by which SGLT2i may modulate hematopoiesis and stimulate erythropoiesis.
Keyphrases